Procter & Gamble (P&G) has agreed to buy the consumer health business of German drugmaker Merck for €3.4billion (US$4.2 billion), as the US group struggles to ignite sales of its household brands.
The acquisition will give P&G, which owns a wealth of brand names from Pampers diapers to Gillette razors, control of vitamin makers including Seven Seas and Neurobion, which are faster-growing than P&G’s household products.
David Taylor, chief executive of P&G, said the over-the-counter healthcare business would offer “steady, broad-based growth.”
The deal was announced on the same day that the company unveiled another quarter of anemic sales growth and shrinking profit margins as it grapples with discounting from retailers and declining pricing power for its decades-old brands. `
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Pfizer Settles Remaining Effexor XR Antitrust Claims for $25.5 Million
Apr 29, 2024 by
CPI
South Korean Regulator Approves LG Uplus and Kakao Mobility EV Charging Venture
Apr 29, 2024 by
CPI
Federal Judge Dismisses Doctors’ Antitrust Suit Against Ohio Health System
Apr 29, 2024 by
CPI
Paramount CEO Bob Bakish Steps Down as Merger Inches Closer
Apr 29, 2024 by
CPI
EU Brands Apple’s iPadOS as Gatekeeper in Tech Crackdown
Apr 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI